Avenda Health highlighted a new American Medical Association (AMA) category III 2024 Current Procedural Terminology (CPT) code for prostate cancer mapping.
The new code (X237T) covers “AI Generated Prostate Cancer Mapping,” described by the AMA as follows:
“Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report.”
Category III designations are temporary codes for new and developing technologies, such as Avenda’s Unfold AI software, Avenda said. Unfold AI integrates patient-specific data from prostate imaging and biopsies and generates a customized cancer probability map in 3D, which enables physicians to visualize the precise location of cancer for informed intervention planning, the company said.
The full set of Category III codes are published annually in the CPT codebook. The most recently approved codes will be posted to the AMA CPT website on January 1, 2024, with an effective implementation date of July 1, 2024, Avenda added.
